Skip to content
Injection Allopathic

G-Neostigmine 0.5 mg/ml injection

Generic: Neostigmine Methyl Sulphate

Company: Not listed yet. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength0.5 mg/ml
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated September 7, 2024.

Compare

Same generic, same strength

Sorted by price per injection. Ask your pharmacist before you switch brands.

Neostigmine Methyl Sulphate 0.5 mg/ml injections

Prices as listed on BestinMeds.

2 brands listed
Neostig, box of 106.07 taka per injection Neostig, box of 56.07 taka per injection
G-Neostigmine, box of 5 (this medicine)10.00 taka per injection

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Neostigmine Methyl Sulphate guide

Indications

Reversal of neuromuscular blockade Neostigmine Methyl Sulphate is indicated for- Reversal of nondepolarising neuromuscular blockade for surgical anesthetic procedures The prevention and treatment of post-operative abdominal distention and urinary retention after mechanical obstruction has been excluded. ... Read more Neostigmine Methyl Sulphate is indicated for- Reversal of nondepolarising neuromuscular blockade for surgical anesthetic procedures The prevention and treatment of post-operative abdominal distention and urinary retention after mechanical obstruction has been excluded. Treatment of the systemic control of Myasthenia Gravis when oral therapy is impractical.

Dosage and administration

Reversal of the effects of Non-depolarizing Neurormuscular Blocking Agents: The usual dose is 0.5 to 2 mg given by slow intravenous injection over 60 seconds; repeated as required. Total dose should not exceed 5 mg (in exceptional cases). When Neostigmine is administered intravenously, it is recommended that Atropine Sulphate (0.6-1.2 mg) also be given intravenously using separate syringe. Prevention of post-operative abdominal distention and urinary retention: 0.25 mg intramuscularly or subcutaneously as soon as possible after operation; repeat every 4 6 hours for 2-3 days. Treatment of post-operative abdominal distention: 0.5 mg intramuscularly or subcutaneously or as required. Treatment of urinary retention: 0.5 mg intramuscularly or subcutaneously. If urination does not occur within an hour, the patient should be catheterized. After the patient has voided, or the bladder has been emptied, continue the 0.5 mg injection every 3 hours, for at least 5 injections. Symptomatic control of Myasthenia Gravis: 0.5 mg intramuscularly or subcutaneously. Subsequent dose should be based on the individual patient's response. Neonates: 50-250 micrograms (0.1 to 0.5 ml) every 4 hours. Children: 200-500 micrograms (0.4 ml to 1 ml) as recommended.

Side effects

Nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). Signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis.

Precautions and warnings

Asthma, bradycardia, recent myocardial infarction, epilepsy, hypotension, parkinsonism, vagotonia, peptic ulceration. Atropine or other antidote to muscarinic effccts may be necessary (particularly when Neostigmine is given by injection), but it should not be given routinely as it may mask signs of overdose.

Pregnancy and lactation

Pregnancy Category C. There are no adequate or well-controlled studies of Neostigmine in either laboratory animals or in pregnantwomen. It is not known whether Neostigmine can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Neostigmine should be given to a pregnant woman only if clearly needed. Nonteratogenic Effects: Anticholinesterase drugs may cause uterine irritability and induce premature labor when given intravenously to pregnant women near term. Nursing Mothers: It is not known whether Neostigmine is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from Neostigmine in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250